Mobirise

WHAT WE DO

Our platform combines defined products with proven workflows, supported by a global network of life sciences experts. Each module can be adopted on its own or integrated into a full launch system.

 

The Sigla Product Suite 

AssetRadar™ – Continuous AI-augmented search and expert evaluation of emerging biopharma assets. 

ExpertRadar™ – Stakeholder mapping and influence analytics across KOLs, payers, and policy leaders. 

ReimbursementRadar™ – Horizon scanning and predictive positioning analysis for clinical guideline updates, payer policy changes, and formulary position forecasting.

 AI & Digital Tools 

MLR Pre-Flight™ – AI-powered review engine that accelerates Medical/Legal/Regulatory submissions. 

AI for Life Sciences Framework – Governance, adoption, and playbook for integrating AI responsibly. 

Modular AI/ML & Data Management Tools – Customizable solutions for evidence generation, engagement analytics, and launch readiness.

Our subject matter expert teams operate across core areas critical to launch success: 

  • HEOR/HTA (HEALTH ECONOMICS & OUTCOMES RESEARCH, HEALTH TECHNOLOGY ASSESSMENT) - Health economists, HEOR study designers data data analysts, and country-specific expert HTA teams in the US, UK, and EU
  • MARKET ACCESS  - Billing & Coding experts, KOLs who participate in guideline and pathway creation, health policy leaders in the US and Europe, and market access marketers
  • PHARMACY, CLINICAL, AND REIMBURSEMENT OPERATIONS - Pharmacy and administrative leaders at academic and community institutions in the US and Europe, focusing on oncology and CGT implementation; US GPO network leaders
  • DIGITAL MARKETING, DIGITAL ENGAGEMENT, AND HEALTH TECH PARTERSHIPS - Experts in digital health and omnichannel marketing, patient engagement, HCP marketing, digital health and health tech partnerships, connected devices, and AI-powered tools
  • CLINICAL DEVELOPMENT, SCIENCE, MEDICAL AFFAIRS, AND SCIENTIFIC COMMUNICATIONS - Physicians and PhD scientists in oncology, biomarkers, and cell therapies with strong PI networks Phase I-III expertise, 
Mobirise